NICOYA年衍药业
/
Back to newsroom
Partnership milestone

Greater China development and commercialization partnership begins

In 2021, OPKO announced an agreement with Nicoya Therapeutics covering the development and commercialization of RAYALDEE in Greater China.

Starting point

In June 2021, OPKO announced a license agreement with Nicoya Therapeutics covering Greater China, including mainland China, Hong Kong, Macau and Taiwan.

Long-term collaboration

The framework connects regional development, regulatory progress and commercialization preparation, forming the basis for later milestones. Local status should always be checked against formal regulatory and company announcements.

Continued collaboration

The parties will continue regional development and commercialization work under the existing framework. Local status should be checked against regulatory and company announcements.

View original sourceOPKO Health · Official press release ↗